# Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)

> **NCT00169585** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 240 (actual)

## Conditions studied

- Prostatic Hyperplasia
- Prostatitis

## Interventions

- **DRUG:** Levofloxacin oral tablets

## Key facts

- **NCT ID:** NCT00169585
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00169585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00169585, "Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00169585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*